CTAG1B and melanoma: Among 25 melanoma patients:CBR: 72%.ORR: 14%Median PFS: 9 monthsMedian OS: 48 months.Robust T‐cell responses and effective antibody production against NY‐ESO‐1 in the majority of patientPatients who had preexisting NY‐ESO‐1‐specific immunity experienced substantial benefitsCD8+ T‐cell responses predominantly targeted NY‐ESO‐1 epitopes in regions p81‐110 and p151‐170, with lower responses in p119‐143 regions